News

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...